Please Wait
Applying Filters...

Annual Sales of Prestwick3_000419 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 96Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4Dulcolax

PharmaCompass
Left Arrow
Right Arrow

01

Brand Name : Dulcolax

arrow
AAPS 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Bisacodyl

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2019 Revenue in Millions : 245

2018 Revenue in Millions : 235

Growth (%) : 4

Sanofi Company Banner

02

Brand Name : Dulcolax

arrow
AAPS 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Bisacodyl

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2020 Revenue in Millions : 284

2019 Revenue in Millions : 272

Growth (%) : 4

Sanofi Company Banner

03

Brand Name : Dulcolax

arrow
AAPS 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Bisacodyl

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2018 Revenue in Millions : 244

2017 Revenue in Millions : 238

Growth (%) : 2%

Sanofi Company Banner

04

Brand Name : Dulcolax

Bisacodyl

arrow
AAPS 2024
Not Confirmed